The $290M capital raise removes near-term financing risk and funds the RAS program through Phase I data in 2027. Traders should watch for enrollment updates and potential early data from the AN9025 QW arm. The license revenue provides a modest non-dilutive boost but is not recurring.
Price Chart
Executive Summary
Adlai Nortye reported H1 2026 results with revenue of $13.1M (from nil) from an AN9025 license agreement, net loss narrowing 70.9% to $5.3M, and EPS of -$0.04. The company raised $290M in two private placements, boosting cash to $231.9M, and provided pipeline updates with Phase I data for pan-RAS(ON) inhibitor AN9025 expected in 1H27. The strong cash position and pipeline progress are positive, though the company remains pre-revenue and early-stage.
Key Financial Metrics
Key Facts
- Revenue of $13.1M for H1 2026 vs nil in H1 2025, from AN9025 license agreement with Jiangsu Aosaikang
- Net loss narrowed 70.9% to $5.3M from $18.3M; EPS -$0.04 vs -$0.19
- Cash and short-term investments of $231.9M as of June 30, 2026, up from $8.1M at Dec 31, 2025
- Raised $140M in Feb 2026 and $150M in Apr 2026 via oversubscribed private placements
- Phase I enrollment ongoing for AN9025 (pan-RAS(ON) inhibitor) with initial data expected 1H27
- AN4035 (RAS-inhibitor ADC) received HREC approval in Australia; first patient dosing expected 2H26
Financial Impact
Cash position strengthened by $223.8M to $231.9M, providing runway through key clinical milestones. Revenue of $13.1M is non-recurring license income.
Risk Factors
- Clinical trial failure or delays for AN9025 and other pipeline candidates
- Dilution from future equity offerings if cash runway shortens
- No approved products; reliance on early-stage pipeline for value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345240 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.71 (−11.41%) |
Oct 15, 2026 12d ago | Press Release | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.71 (−11.41%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.71 (−33.06%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.71 (−33.06%) |
Sep 16, 2026 5w ago | EFFECT | $15.52 $15.75 | ▲ +1.48% | ▼ −0.34% | $10.71 (−30.99%) |
Aug 26, 2026 8w ago | 6-K | $15.06 $13.86 | ▼ −8.00% | ▼ −7.88% | $10.71 (−28.88%) |
Aug 19, 2026 9w ago | 6-K | $14.33 $15.06 | ▲ +5.09% | ▲ +5.48% | $10.71 (−25.26%) |
Aug 14, 2026 10w ago | 6-K | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.71 (−19.17%) |
Aug 14, 2026 10w ago | Press Release | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.71 (−19.17%) |
Aug 3, 2026 12w ago | 6-K | $12.99 $13.23 | ▲ +1.85% | ▼ −0.18% | $10.71 (−17.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers